Adverse Events in Trial Assessing Dara-KRd in Patients With Newly Diagnosed Multiple Myeloma
December 23rd 2021Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses the adverse events experienced by patients with newly diagnosed multiple myeloma who were administered daratumumab, carfilzomib, lenalidomide, and dexamethasone.
Watch
Semaglutide Carries Potential Risk of Worsening Diabetic Retinopathy
Despite demonstrating numerous benefits, semaglutide has also been linked to an increased incidence of diabetic retinopathy, which was initially reported in the SUSTAIN-6 trial.
Read More
David Olson, PhD, the chief innovation officer, head of scientific advisory board, and co-founder of delix therapeutics and an associate professor at University of California, Davis, discusses psychedelics and other psychoplastogens in the treatment of brain and mental health disorders.
Watch
Next Steps in Assessing BOVen Therapy in Patients With Previously Untreated CLL
December 23rd 2021Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses next steps in the research assessing zanubrutinib, obinutuzumab, and venetoclax in the treatment of previously untreated chronic lymphocytic leukemia.
Watch
FDA Approves Apretude, the First, Only Long-acting Injectable Option for HIV Prevention
December 22nd 2021The agency’s approval follows trial results demonstrating the superior efficacy of the cabotegravir long-acting injectable to a daily oral PrEP option in reducing the risk of infection.
Read More
Expert: Pharmacists, USP Worked Together ‘A Hundred Times Faster Than Ever Before’ in 2021
December 22nd 2021Ronald T. Piervincenzi, PhD, CEO of US Pharmacopeia, explains how pharmacists and USP came together in 2021 to work harder than ever before, as well as what can be done now to prepare for the next health crisis.
Watch
TXNIP inhibitors: A New Class of Agents for Diabetes Treatment
TXNIP inhibition could prevent beta cell loss and protect beta cell function to potentially contribute to diabetes management and its complications.
Read More
Assessing Trial Results for All Endpoints for Dara-KRd in Treatment of Multiple Myeloma
December 22nd 2021Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses the results for all of the trial endpoints assessing daratumumab, carfilzomib, lenalidomide, and dexamethasone for patients with newly diagnosed multiple myeloma.
Watch
Safety, Efficacy of BOVen Therapy in Patients With Previously Untreated CLL
December 22nd 2021Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses trial results showing the safety and efficacy of zanubrutinib, obinutuzumab, and venetoclax in the treatment of previously untreated chronic lymphocytic leukemia.
Watch
Link Is Seen to Commonly Screened Protein During Pregnancy
December 22nd 2021The data highlight a new role for pregnancy-associated plasma protein A, known as PAPP-A, in gestational diabetes, with translational potential as both a diagnostic tool and therapeutic target, according to the investigators.
Read More